Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders

MC Michel, L Cardozo, CJ Chermansky, F Cruz… - Pharmacological …, 2023 - ASPET
Overactive bladder syndrome with and without urinary incontinence and related conditions,
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …

Long-term surveillance and management of urological complications in chronic spinal cord-injured patients

SY Wu, JF Jhang, HH Liu, JT Chen, JR Li… - Journal of Clinical …, 2022 - mdpi.com
Bladder dysfunction is a common complication after chronic spinal cord injury (SCI). Patients
may experience renal function loss, urinary tract infection (UTI), urolithiasis, bladder cancer …

[HTML][HTML] Current pharmacotherapy of overactive bladder

EI Kreydin, CM Gomes, F Cruz - International braz j urol, 2021 - SciELO Brasil
Overactive bladder is a symptom complex consisting of bothersome storage urinary
symptoms that is highly prevalent among both sexes and has a significant impact on quality …

Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: a double‐blind, randomized placebo‐controlled trial (Parkinson's …

SY Cho, SJ Jeong, S Lee, J Kim, SH Lee… - Neurourology and …, 2021 - Wiley Online Library
Aims This study aimed to investigate the efficacy and safety of mirabegron for Parkinsonism
patients with overactive bladder (OAB) symptoms in a randomized, placebo‐controlled …

Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study

M Kinjo, K Masuda, Y Nakamura, J Miyakawa… - Urology, 2023 - Elsevier
Objective To compare the efficacy and safety of mirabegron versus vibegron in
postmenopausal women with treatment-naïve overactive bladder (OAB). Methods We …

Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient

A Makhani, M Thake, W Gibson - Clinical interventions in aging, 2020 - Taylor & Francis
Lower urinary tract symptoms, including urgency, urgency incontinence, frequency, and
nocturia, are highly prevalent in older adults and are associated with significant morbidity …

The differential risk of mortality among users of overactive bladder anticholinergic medications and β3 agonists

B Welk - European Urology Focus, 2023 - Elsevier
Anticholinergic overactive bladder (OAB) medications have been studied in large
observational studies to determine if they are associated with a greater risk of mortality …

Pharmacology of the lower urinary tract: update on LUTS treatment

P Abreu-Mendes, J Silva… - Therapeutic advances in …, 2020 - journals.sagepub.com
The number of compounds used in the pharmacological treatment of lower urinary tract
symptoms (LUTS) of patients who do not respond to conservative measures has been …

Are beta 3 adrenergic agonists now the preferred pharmacologic management of overactive bladder?

C Fogaing, AH Mossa, L Campeau - Current urology reports, 2020 - Springer
Abstract Purpose of the Review This paper discusses the recent evidence supporting beta 3
adrenergic agonists as the preferred pharmacological management of overactive bladder …

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial

SM Hsiao, FC Tu, TC Su, PC Wu, HH Lin - Scientific Reports, 2022 - nature.com
The study aims to elucidate the impact of mirabegron versus solifenacin on autonomic
function and peripheral arterial conditions in women with overactive bladder syndrome …